Suchergebnisse - "Bedossa, Pierre"

PubPharm (570)

1

Prospective Comparison of Attenuation Imaging and Controlled Attenuation Parameter for Liver Steatosis Diagnosis in Patients With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2024

von Dioguardi Burgio, M. | Castera, L. | Oufighou, M. | +12

2

Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes

enthalten in: Journal of hepatology | 2024

von Castera, L. | Garteiser, P. | Laouenan, C. | +86

3

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

enthalten in: The New England journal of medicine | 2024

von Harrison, S. | Bedossa, P. | Guy, C. | +127

4

Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH

enthalten in: Journal of hepatology | 2024

von Boesch, M. | Lindhorst, A. | Feio-Azevedo, R. | +23

5

Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis : AURORA Phase III Randomized Study

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2024

von Anstee, Q. | Neuschwander-Tetri, B. | Wai-Sun Wong, V. | +8

CommentIn: Clin Gastroenterol Hepatol. 2024 Jan;22(1):16-19. - PMID 37517632

6

Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

enthalten in: Alimentary Pharmacology & Therapeutics | 2024

von Harrison, S. | Ratziu, V. | Anstee, Q. | +11

7

Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

enthalten in: Alimentary pharmacology & therapeutics | 2024

von Harrison, S. | Ratziu, V. | Anstee, Q. | +11

8

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY) : a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Harrison, S. | Frias, J. | Neff, G. | +17

9

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

enthalten in: Hepatology (Baltimore, Md.) | 2023

von Rinella, M. | Lazarus, J. | Ratziu, V. | +151

10

Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis

enthalten in: Alimentary pharmacology & therapeutics | 2023

von Poynard, T. | Deckmyn, O. | Peta, V. | +8

CommentIn: Aliment Pharmacol Ther. 2023 Nov;58(10):1111-1112. - PMID 37885167

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[57]